Author

A. Marzi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 9 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 11 Research Focus:host-pathogen & immune response· 10 Organism:mouse· 4 Organism:non-human primate· 4 Research Focus:drug response / drug discovery· 3 Assay:proteomics· 3 Assay:bulk RNA-seq· 2 Research Focus:benchmarking· 1

Frequent Co-Authors

K. L. O'Donnell· 5 shared C. S. Clancy· 4 shared F. Feldmann· 4 shared K. Shifflett· 4 shared P. Fletcher· 4 shared W. Furuyama· 4 shared P. W. Hanley· 3 shared T. Gourdine· 3 shared

Activity by Year

2020-2024 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

K. L. O'Donnell

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

A viral vaccine design harnessing prior BCG immunization confers protection against Ebola virus

T. W. Ng, W. Furuyama, A. S. Wirchnianski, N. A. Saavedra-Avila, C. T. Johndrow, K. Chandran, W. R. Jacobs, A. Marzi, S. A. Porcelli

This paper demonstrates a viral vaccine strategy using BCG-induced Th cells to enhance antibody responses against Ebola virus, providing protection in a mouse model.

bioRxiv · May 28, 2024 · PreprintImmunology

A bivalent Adenovirus-Vectored Vaccine induces a measurable humoral response, but does not protect cynomolgus macaques against a lethal challenge with Sudan virus

S. van Tol, P. Fletcher, F. Feldmann, R. K. Mukesh, J. R. Port, S. Gallogly, J. E. Schulz, J. F. Roderick, R. Makinson, A. Carmody, L. Myers, J. Lovaglio, B. J. Smith, A. Okumura, C. Shaia, , N. van Doremalen

This study evaluates a bivalent Adenovirus-Vectored Vaccine in cynomolgus macaques against Sudan virus, finding it induces humoral responses but does not confer protection against lethal challenge.

bioRxiv · Oct 20, 2023Microbiology

VSV-based vaccine provides species-specific protection against Sudan virus challenge in macaques

A. Marzi, P. Fletcher, F. Feldmann, G. Saturday, P. W. Hanley, H. Feldmann

This study develops a VSV-based vaccine against Sudan virus and shows it protects macaques from lethal infection, highlighting the need for specific countermeasures against filoviruses.

bioRxiv · Oct 27, 2022 · PreprintMicrobiology

Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine

K. L. O'Donnell, F. Feldmann, B. Kaza, C. S. Clancy, P. W. Hanley, P. Fletcher, A. Marzi

A single low-dose VSV-based vaccine protects nonhuman primates from lethal Marburg virus disease regardless of administration timing.

bioRxiv · Sep 17, 2022Immunology

Integrity of membrane fluidity and fatty acid environment are necessary for Ebola virus VP40 assembly and release of viral particles

S. Amiar, K. A. Johnson, M. L. Husby, A. Marzi, R. V. Stahelin

This study shows that membrane fluidity and fatty acid composition are critical for Ebola virus VP40 assembly and viral particle release.

bioRxiv · Aug 24, 2022 · PreprintMicrobiology

Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern

A. Marzi, A. Griffin, K. L. O'Donnell, K. Shifflett, J.-P. Lavik, P. M. Russell, M. K. Zimmerman, R. F. Relich

The paper examines serum from early pandemic SARS-CoV-2 patients, finding limited cross-neutralization against variants of concern.

bioRxiv · Nov 10, 2021Microbiology

Optimization of single dose VSV-based COVID-19 vaccination in hamsters

K. L. O'Donnell, C. S. Clancy, A. J. Griffin, K. Shifflett, T. Gourdine, T. Thomas, C. M. Long, W. Furuyama, A. Marzi

This study evaluates two VSV-based COVID-19 vaccines in hamsters, showing intranasal vaccination provides rapid protection against multiple SARS-CoV-2 variants.

bioRxiv · Sep 3, 2021Microbiology

Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model

K. L. O'Donnell, A. N. Pinski, C. S. Clancy, T. Gourdine, K. Shifflett, P. Fletcher, I. Messaoudi, A. Marzi

This study compares the pathogenic and transcriptomic effects of SARS-CoV-2 variants B.1.1.7 and B.1.351 to the ancestral strain in Syrian golden hamsters, finding distinct humoral responses and transcriptional profiles.

bioRxiv · Jul 11, 2021Microbiology

Ebola virus glycoprotein domains associated with protective efficacy

B. Bhatia, W. Furuyama, T. Hoenen, H. Feldmann, A. Marzi

The paper identifies regions of the Ebola virus glycoprotein that are essential for vaccine vector replication but not for protective immunity.

bioRxiv · May 22, 2021Microbiology

Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine

W. Furuyama, K. Shifflett, A. N. Pinksi, A. J. Griffin, F. Feldmann, A. Okumura, T. Gourdine, A. Jankeel, J. Lovaglio, P. W. Hanley, T. Thomas, C. S. Clancy, I. Messaoudi, K. L. O'Donnell, A. Marzi

A single-dose VSV-based vaccine protected nonhuman primates from COVID-19 within 10 days when administered intramuscularly but not intranasally.

bioRxiv · Jan 19, 2021 · PreprintMicrobiology

K18-hACE2 mice develop respiratory disease resembling severe COVID-19

C. K. Yinda, J. R. Port, T. J. Bushmaker, I. Offei Owusu, V. A. Avanzato, R. J. Fischer, J. E. Schulz, M. G. Holbrook, M. J. Hebner, R. Rosenke, T. Thomas, A. Marzi, S. M. Best, E. de Wit, C. Shaia, , V. Munster

This paper shows that K18-hACE2 mice develop severe respiratory disease upon SARS-CoV-2 infection, resembling human severe COVID-19 with lung pathology and systemic inflammation.

bioRxiv · Aug 11, 2020Microbiology